



**INSTITUTIONAL ETHICS COMMITTEE**  
(DHR File No. EC/NEW/INST/2020/1079)  
**INDIAN INSTITUTE OF TECHNOLOGY MADRAS**  
Sardar Patel Road, Adyar Chennai – 600 036.

**Email:** iec@iitm.ac.in

**Phone:** 044 – 2257 4929

**APPLICATION FOR ANNUAL REPORT / EXTENSION REQUEST**

(Form to be filled by the Principal Investigator)

Title of the Research Proposal	
IITM – IEC Protocol No.	
Date of IEC Approval	
Validity of approval	
Duration of the project / trial	
Period of continuing review	

1. Name of the Principal Investigator (PI) :  
Designation :  
Contact address :  
Email Id & Mobile No. :
2. Name of the Co-Investigator (Co-PI) :  
Designation :  
Contact address :  
Email Id & Mobile No. :
3. Provide details
  - i. Background of the work (250words) :
  - ii. Approved objectives (bullet points) :
  - iii. Brief methodology (400words) :
4. Does the study involve recruitment of participants? Yes  No 
  - i. If yes, what is the sample size approved :
  - ii. No. of participants screened :
  - iii. No. of participants enrolled / recruited :
5. Is participant recruitment continuing : Yes  No
6. Are there any dropouts? : Yes  No
7. Have any participants withdrawn from this study since the last approval: Yes  No   
(If yes, total no. withdrawn and reasons)
8. Is the study likely to extend beyond the stated period? Yes  No   
(If yes, provide reasons for the extension)
9. Have there been any amendments in the research protocol / informed consent document (ICD) during the past approval period? Yes  No 
  - i. If yes, date of approval for revised protocol and ICD :
  - ii. In case of amendments in the research protocol / ICD, was re-consent sought from participants? Yes / No (If yes, provide details)



**INSTITUTIONAL ETHICS COMMITTEE**  
(DHR File No. EC/NEW/INST/2020/1079)  
**INDIAN INSTITUTE OF TECHNOLOGY MADRAS**  
Sardar Patel Road, Adyar Chennai – 600 036.

**Email:** iec@iitm.ac.in

**Phone:** 044 – 2257 4929

10. Has there been any protocol deviations / violations that occurred during this period?
  - i. If yes, number of deviations \_\_\_\_\_ :
  - ii. Have you reported the deviations to EC? If not, state reasons
11. Explain the summary of data obtained and key findings:
12. Are there any publications or presentations from the study during this period? Yes / No  
(If yes, give details and attach published paper)
13. Is any new information available that changes the benefit -risk analysis of human participants involved in this study? Yes / No (If yes, discuss in detail)
14. Have any ethical concerns occurred during this period? Yes  No   
(If yes, give details)
15. Have any adverse events been noted since the last review? Yes  No  NA   
(If yes, describe in brief)
16. Have any Serious Adverse Events (SAEs) occurred since last review? Yes  No  NA   
(If yes, number of SAEs and type of SAEs)
17. Is the SAE related to the study? Yes  No
18. Have you reported the SAE to EC? Yes  No   
(If no, state reasons)
19. Principal Investigator \_\_\_\_\_ :  
Signature & Seal \_\_\_\_\_ :  
Date \_\_\_\_\_ :
20. Co - Principal Investigator \_\_\_\_\_ :  
Signature & Seal \_\_\_\_\_ :  
Date \_\_\_\_\_ :